Canopy Growth (CGC) Shares Outstanding (Weighted Average) (2017 - 2025)
Canopy Growth's (CGC) quarterly Shares Outstanding (Weighted Average) came in at $11.1 million in Q4 2025, little changed year-on-year from $11.1 million in Q4 2024, and down 94.42% quarter-over-quarter from $199.1 million in Q3 2025.
Canopy Growth (CGC) Shares Outstanding (Weighted Average) (2017 - 2025) Analysis & Trends
Canopy Growth has disclosed Shares Outstanding (Weighted Average) across 9 years of filings, most recently posting $11.1 million for Q4 2025.
- Shares Outstanding (Weighted Average) for Q4 2025 came in at $11.1 million, changed 0.36% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.1 million (changed 0.36% YoY), and the FY2025 annual result was $10.8 million, up 39.12% from the prior year.
- Shares Outstanding (Weighted Average) came in at $11.1 million for Q4 2025 at Canopy Growth, down from $199.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $312.5 million in Q2 2022 to a low of $7.8 million in Q1 2024.
- The 5-year median for Shares Outstanding (Weighted Average) is $49.5 million (2023), against an average of $100.8 million.
- Across the five-year window, Shares Outstanding (Weighted Average) plunged 90.8% in 2021 and soared 440.11% in 2024, its largest moves.
- Canopy Growth's Shares Outstanding (Weighted Average) stood at $309.7 million in 2021, then plunged by 89.22% to $33.4 million in 2022, then jumped by 82.41% to $60.9 million in 2023, then tumbled by 81.71% to $11.1 million in 2024, then fell by 0.36% to $11.1 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $11.1 million (Q4 2025), $199.1 million (Q3 2025), and $135.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 1.16 Bn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | 422.10 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 43.50 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | 100.50 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | 5.11 Bn |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | 497.70 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | 166.20 Mn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | 64.74 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | 88.01 Mn |
| 10 | Canopy Growth | 11.16 Mn | -137.54 Mn | 15.39 Mn | 11.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.10 Mn |
| Sep 30, 2025 | 199.12 Mn |
| Jun 30, 2025 | 135.91 Mn |
| Mar 31, 2025 | 10.79 Mn |
| Dec 31, 2024 | 11.14 Mn |
| Sep 30, 2024 | 60.88 Mn |
| Jun 30, 2024 | 57.94 Mn |
| Mar 31, 2024 | 7.76 Mn |
| Dec 31, 2023 | 60.91 Mn |
| Sep 30, 2023 | 11.27 Mn |
| Jun 30, 2023 | 40.98 Mn |
| Mar 31, 2023 | 9.48 Mn |
| Dec 31, 2022 | 33.39 Mn |
| Sep 30, 2022 | 98.29 Mn |
| Jun 30, 2022 | 312.53 Mn |
| Mar 31, 2022 | 10.12 Mn |
| Dec 31, 2021 | 309.74 Mn |
| Sep 30, 2021 | 312.42 Mn |
| Jun 30, 2021 | 312.44 Mn |
| Mar 31, 2021 | 10.04 Mn |